@article {Medi{\'c}2022.04.08.22273571, author = {Sne{\v z}ana Medi{\'c} and Cleo Anastassopoulou and Zagorka Lozanov-Crvenkovi{\'c} and Vladimir Vukovi{\'c} and Nata{\v s}a Dragni{\'c} and Vladimir Petrovi{\'c} and Mioljub Risti{\'c} and Tatjana Pustahija and Zoran Gojkovi{\'c} and Athanasios Tsakris and John P. A. Ioannidis}, title = {Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: a population-level study}, elocation-id = {2022.04.08.22273571}, year = {2022}, doi = {10.1101/2022.04.08.22273571}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Data on the rate and severity of SARS-CoV-2 reinfections in real-world settings are scarce and the effects of vaccine boosters on reinfection risk are unknown.Methods In a retrospective cohort study, registered SARS-CoV-2 laboratory-confirmed Vojvodina residents, between March 6, 2020 and October 31, 2021, were followed for reinfection >=90 days after primary infection. Data were censored at the end of follow-up (January 31, 2022) or death. The reinfection risk was visualized with Kaplan-Meier plots. To examine the protective effect of vaccination, the subset of individuals with primary infection in 2020 (March 6-December 31) were matched (1:2) with controls without reinfection.Findings Until January 31, 2022, 13,792 reinfections were recorded among 251,104 COVID-19 primary infections (5.49\%). Most reinfections (86.8\%) were recorded in January 2022. Reinfections were mostly mild (99.2\%). Hospitalizations were uncommon (1.8\% vs. 3.70\% in primary infection) and COVID-19 deaths were very rare (n=20, case fatality rate 0.15\%). The overall incidence rate of reinfections was 5.99 (95\% CI 5.89-6.09) per 1,000 person-months. The reinfection risk was estimated as 0.76\% at six months, 1.36\% at nine months, 4.96\% at 12 months, 16.7\% at 15 months, and 18.9\% at 18 months. Unvaccinated (OR=1.23; 95\%CI=1.14-1.33), incompletely (OR=1.33; 95\%CI=1.08-1.64) or completely vaccinated (OR=1.50; 95\%CI=1.37-1.63), were modestly more likely to be reinfected compared with recipients of a third (booster) vaccine dose.Interpretation SARS-CoV-2 reinfections were uncommon until the end of 2021 but became common with the advent of Omicron. Very few reinfections were severe. Boosters may modestly reduce reinfection risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Institute of Public Health of Vojvodina waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.}, URL = {https://www.medrxiv.org/content/early/2022/04/22/2022.04.08.22273571}, eprint = {https://www.medrxiv.org/content/early/2022/04/22/2022.04.08.22273571.full.pdf}, journal = {medRxiv} }